BioCentury on BioBusiness,
Product Discovery & Development
Table: Building cycles
Back to the parent article
Published on
Monday, September 17, 2012
At least 12 companies are developing macrocycle and
constrained-peptide synthesis technologies. (A) Disclosed financings;
(B) Formed following the merger of Tranzyme Inc. with Neokima Inc. in 2003;
Source: BCIQ: BioCentury Online Intelligence; company press releases and
websites
|
Company
|
Platform
technology
|
Lead
program
|
Founded
|
Raised
(A)
|
|
Aileron
Therapeutics Inc.
|
Alpha-helical
stapled peptides
|
ALRN-5281,
a preclin long-acting growth hormone- releasing hormone (GHRH) agonist for
adult growth hormone (GH) deficiency, HIV lipodystrophy and GH-deficient
abdominal obesity
|
2005
|
$60M
|
|
Bicycle
Therapeutics Ltd.
|
Phage
display of bicyclic peptides
|
Undisclosed
preclin programs
|
2009
|
$6.1M
|
|
Encycle
Therapeutics Inc.
|
Amphoteric
cyclization
|
Undisclosed
preclin programs
|
2012
|
$1M
|
|
Ensemble
Therapeutics Corp.
|
DNA-programmed
chemistry for macrocycle synthesis
|
Preclin
antagonist of interleukin-17 (IL-17) for autoimmune/inflammatory diseases
|
2004
|
$38.5M
|
|
Lanthio
Pharma B.V.
|
Lanthionine
constrained peptides produced in Lactococcus lactis
|
Preclin
lanthionine-Ang(1-7) peptide targeting the MAS receptor to treat acute lung
injury (partnered with Tarix Pharmaceuticals Inc.)
|
2010
|
$784K
|
|
Oncodesign
S.A.
|
Nanocyclix
medicinal chemistry
|
Disclosed
preclin programs include inhibitors of kinases including leucine-rich repeat
kinase 2 (LRRK2) to treat Parkinson's disease (PD) (partnered with Ipsen
Group (Euronext:IPN; Pink:IPSEY); FMS-like tyrosine kinase 3 (FLT3;
CD135) and germ cell associated 2 (haspin) for cancer; neurotrophic tyrosine
kinase receptor (TRK) for pain; and CDC-like kinase (CLK) for CNS indications
|
1995
|
$4.6M
|
|
Pepscan
Therapeutics B.V.
|
CLIPS
(chemical linkage of peptides onto scaffolds)
|
Disclosed
preclin programs include an HIV-fusion inhibitor (partnered with Johnson
& Johnson (NYSE:JNJ))
|
2000
|
$14.8M
|
|
PeptiDream
Inc.
|
mRNA
display of modified cyclic peptides containing natural and unnatural amino
acids
|
Undisclosed
preclin programs
|
2006
|
ND
|
|
Polyphor
Ltd.
|
MacroFinder
macrocycle platform and PEMfinder (protein epitope mimetics) cyclic peptide
platform
|
POL6326,
a CXC chemokine receptor 4 (CXCR4) inhibitor in Ph II to treat cancer using
hematopoietic stem cell (HSC) transplantation
|
1996
|
ND
|
|
Protagonist
Therapeutics Inc.
|
Disulfide
rich peptides (DRPs)
|
Disclosed
preclin programs include orally stable interleukin-6 (IL-6) peptide
antagonists and oral DRPs for inflammatory bowel disease (IBD)
|
2006
|
$9M
|
|
Ra
Pharmaceuticals Inc.
|
mRNA
display of modified cyclic peptides containing natural and unnatural amino
acids
|
Preclin
plasma kallikrein inhibitor for hereditary angioedema (HAE)
|
2008
|
$27M
|
|
Tranzyme
Inc. (NASDAQ:TZYM)
|
MATCH
(macrocyclic template chemistry)
|
TZP-102,
an oral ghrelin agonist in Ph II for diabetic gastroparesis
|
2003
(B)
|
$140M
|
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]